Abstract: A cultured spherical body that is capable of easily performing quantitative analysis of a region containing brain neurons, useful as a supply source of neurons for transplantation, and can be used suitably for drug discovery screening for neurological diseases and compound evaluation systems is obtained. Provided are a cultured spherical body including a first cell layer containing neural stem cells and/or neural progenitor cells and a second cell layer containing brain neurons, wherein the first cell layer is present in the superficial portion of the cultured spherical body, and a method for producing the cultured spherical body.

Abstract: An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Abstract: A a prophylactic or therapeutic agent for RNA virus-related diseases is provided, the prophylactic or therapeutic agent containing, as an active ingredient, at least one compound selected from the group consisting of a selective estrogen receptor modulator, an anti-tuberculosis drug, a CysLT1 receptor antagonist, a peroxisome proliferator-activated receptor ? (PPAR?) agonist, an arachidonate 5-lipoxygenase (5-LOX) inhibitor, a derivative thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate thereof.

Abstract: The present invention aims to provide a neuron degeneration inhibitor. The present invention relates to a neuron degeneration inhibitor comprising a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

Abstract: A prophylactic or therapeutic agent for tauopathy, containing an inhibitor of ?2? of the voltage-dependent calcium channel is provided by the present invention.

Abstract: A display control device includes: a circle setting unit that sets a reference circle that serves as the reference for a scale mark layout; a scale mark position determining unit that determines the position of a scale mark on the reference circle; a rectangle setting unit that sets a number display rectangle of the size corresponding to the number of digits of the indication number indicating the value corresponding to the scale mark; a rectangle position determining unit that determines the layout position of the number display rectangle from the position of the scale mark, using a calculating formula that has been set on the basis of the size of the reference circle and the size of the number display rectangle; and a number display unit that displays a number in the number display rectangle, and the calculating formula is designed so that, in a case where a straight line extending through the center of the reference circle on a display screen is set as a symmetrical axis, number display rectangles for disp

Abstract: An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least an intractable neurological disease is associated with an image obtained by imaging the cells of the intractable neurological disease differentiated from the pluripotent stem cells, and predict an onset of the intractable neurological disease of the subject based on output results of the model to which the images were input.

Abstract: A display processing device includes: a processor to execute a program; and a memory to store the program which, when executed by the processor, performs processes of: (a) extracting a plurality of movement lines representing trajectories of moving bodies that leave a first area and arrive in a second area and/or trajectories of moving bodies that leave the second area and arrive in the first area; (b) obtaining, for each of the movement lines extracted by process (a), N-1 division points by dividing the movement line by a division number N, N being an integer not less than 2; (c) calculating N-1 average points by averaging coordinates of the division points obtained by process (b) and belonging to the different movement lines; and (d) drawing a movement line that passes through the N-1 average points obtained by process (c), the first area, and the second area.

Abstract: An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.

Abstract: An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Abstract: A display control device includes: a circle setting unit that sets a reference circle that serves as the reference for a scale mark layout; a scale mark position determining unit that determines the position of a scale mark on the reference circle; a rectangle setting unit that sets a number display rectangle of the size corresponding to the number of digits of the indication number indicating the value corresponding to the scale mark; a rectangle position determining unit that determines the layout position of the number display rectangle from the position of the scale mark, using a calculating formula that has been set on the basis of the size of the reference circle and the size of the number display rectangle; and a number display unit that displays a number in the number display rectangle, and the calculating formula is designed so that, in a case where a straight line extending through the center of the reference circle on a display screen is set as a symmetrical axis, number display rectangles for disp

Abstract: The present invention provides a prophylactic and/or therapeutic agent for ALS containing a Src/c-Abl pathway inhibitor.

Abstract: An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.

Abstract: The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. A method of generating a motor neuron from a pluripotent stem cell, comprising the following steps in order from (1) to (2): (1) introducing one or more nucleic acids encoding Lhx3, Ngn2, and Isl1 into a pluripotent stem cell; and (2) maintaining expression of the Lhx3, Ngn2, and Isl1 for three days or more.

Abstract: An object of the present invention is to provide a method for screening for a prophylactic or therapeutic agent for tauopathy capable of blocking the propagation of tau-mediated neurodegeneration. A method for screening for a prophylactic or therapeutic agent for tauopathy, comprising the following steps (1) to (3): (1) contacting neurons having a mutant MAPT gene with a test substance; (2) measuring any one index selected from the group consisting of the following (a) to (e) in the neurons: (a) the amount of a tau oligomer in a culture supernatant.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), which contains one or more kinase inhibitors selected from the group consisting of an epithelial cell growth factor receptor (EGFR) inhibitor, a fibroblast growth factor receptor (FGFR) inhibitor, an Aurorakinase inhibitor, a protein kinase A (PKA) inhibitor, a protein kinase C (PKC) inhibitor, an MEK inhibitor, an Met inhibitor, a JNK inhibitor, a Syk inhibitor and a JAK inhibitor, a prostaglandin analogue and an estrogen receptor antagonist, or one or more kinase inhibitors selected from the group consisting of Tivozanib and an analog thereof, SB 216763, Cdk2 Inhibitor II, BUDESONIDE, RIBOFLAVIN, alpha-TOCHOPHEROL, AMODIAQUINE, SU9516, Sunitinib and an analog thereof, GSK-3 Inhibitor XIII, Bisindolylmaleimide I, HYDROQUINONE, FLUNISOLIDE, MGCD-265, Indirubin-3?-monoxime, HYDRASTINE (1R,9S), PIPERINE, BUTAMBEN, Axitinib and an analog thereof, APOMORPHINE, FENBUFEN, Bosutinib (SKI-606) and an analog

Abstract: The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. A method of generating a motor neuron from a pluripotent stem cell, comprising the following steps in order from (1) to (2): (1) introducing one or more nucleic acids encoding Lhx3, Ngn2, and Isl1 into a pluripotent stem cell; and (2) maintaining expression of the Lhx3, Ngn2, and Isl1 for three days or more.